{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:02:34Z","timestamp":1771272154109,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"SK Biopharmaceuticals Co., Ltd"},{"name":"Ignis Therapeutics (Shanghai) Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03432-z","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:19:33Z","timestamp":1766391573000},"page":"688-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Adjunctive Cenobamate in Chinese Participants with Focal Seizure"],"prefix":"10.1007","volume":"43","author":[{"given":"Peimin","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songqing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suiqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huapin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiancheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liou","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanran","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-4125","authenticated-orcid":false,"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"3432_CR1","unstructured":"World Health Organization. Epilepsy: a public health imperative [Internet]. Geneva: World Health Organization; [cited 2025 Jan 27]. p. 146 (2019). Available from: https:\/\/iris.who.int\/handle\/10665\/325293."},{"key":"3432_CR2","doi-asserted-by":"crossref","unstructured":"Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296\u2013303.","DOI":"10.1212\/WNL.0000000000003509"},{"issue":"9","key":"3432_CR3","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1212\/01.WNL.0000059867.35547.DE","volume":"60","author":"WZ Wang","year":"2003","unstructured":"Wang WZ, Wu JZ, Wang DS, et al. The prevalence and treatment gap in epilepsy in China: an ILAE\/IBE\/WHO study. Neurology. 2003;60(9):1544\u20135.","journal-title":"Neurology"},{"key":"3432_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.994305","author":"Z Qiu","year":"2022","unstructured":"Qiu Z, Jiang Y. Is there an epilepsy belt of high prevalence rate in China? Front Neurol. 2022. https:\/\/doi.org\/10.3389\/fneur.2022.994305.","journal-title":"Front Neurol"},{"issue":"6","key":"3432_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0758-6","volume":"17","author":"RS Fisher","year":"2017","unstructured":"Fisher RS. The new classification of seizures by the International League Against Epilepsy 2017. Curr Neurol Neurosci Rep. 2017;17(6):48.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"3432_CR6","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/epi.18338","volume":"66","author":"S Beniczky","year":"2025","unstructured":"Beniczky S, Trinka E, Wirrell E, et al. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia. 2025;66(6):1804\u201323.","journal-title":"Epilepsia"},{"issue":"6","key":"3432_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/ncpneuro0521","volume":"3","author":"S Sisodiya","year":"2007","unstructured":"Sisodiya S. Etiology and management of refractory epilepsies. Nat Rev Neurol. 2007;3(6):320\u201330.","journal-title":"Nat Rev Neurol"},{"key":"3432_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/11795735231209209","volume":"15","author":"CL Gunasekera","year":"2023","unstructured":"Gunasekera CL, Sirven JI, Feyissa AM. The evolution of antiseizure medication therapy selection in adults: is artificial intelligence-assisted antiseizure medication selection ready for prime time? J Cent Nerv Syst Dis. 2023;15:11795735231209209.","journal-title":"J Cent Nerv Syst Dis"},{"issue":"Suppl. 2","key":"3432_CR9","first-page":"14","volume":"9","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S. New evidence in adjunctive treatment of focal-onset seizures in adults: a critical appraisal. Glob Reg Health Technol Assess. 2022;9(Suppl. 2):14\u20139.","journal-title":"Glob Reg Health Technol Assess"},{"key":"3432_CR10","unstructured":"Ighodaro ET, Maini K, Arya K, Sharma S. Focal Onset Seizure. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; (2025) [cited 2025 Jan 31]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500005\/."},{"key":"3432_CR11","unstructured":"Xcopri (cenobamate)-NDA approval [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/212839Orig1s000ltr.pdf."},{"issue":"3","key":"3432_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/epi4.12757","volume":"8","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Santos-Carrasco D, Cabezudo-Garc\u00eda P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program. Epilepsia Open. 2023;8(3):918\u201329.","journal-title":"Epilepsia Open"},{"issue":"6","key":"3432_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs. 2021;35(6):609\u201318.","journal-title":"CNS Drugs"},{"issue":"2","key":"3432_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/neurolint13020026","volume":"13","author":"DR Latimer","year":"2021","unstructured":"Latimer DR, Edinoff AN, Ruff RD, et al. Cenobamate, a sodium channel inhibitor and positive allosteric modulator of GABAA ion channels, for partial onset seizures in adults: a comprehensive review and clinical implications. Neurol Int. 2021;13(2):252\u201365.","journal-title":"Neurol Int"},{"issue":"22","key":"3432_CR15","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, et al. Randomized phase\u00a02 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000009530.","journal-title":"Neurology"},{"issue":"1","key":"3432_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348.","journal-title":"Lancet Neurol"},{"key":"3432_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107796","volume":"116","author":"R Elizebath","year":"2021","unstructured":"Elizebath R, Zhang E, Coe P, Gutierrez EG, Yang J, Krauss GL. Cenobamate treatment of focal-onset seizures: quality of life and outcome during up to eight years of treatment. Epilepsy Behav. 2021;116:107796.","journal-title":"Epilepsy Behav"},{"key":"3432_CR18","doi-asserted-by":"crossref","unstructured":"Misra SN, Ferrari L, Hong Z, et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures, with optional open-label extension [Internet]. American Epilepsy Society. [Cited 2025 Jan 28]. Available from: https:\/\/aesnet.org\/abstractslisting\/a-randomized-double-blind-placebo-controlled-multicenter-study-to-evaluate-the-efficacy-and-safety-of-adjunctive-cenobamate-in-asian-patients-with-focal-seizures-with-optional-open-label-extension.","DOI":"10.1212\/WNL.0000000000208538"},{"issue":"S1","key":"3432_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/epi.14458","volume":"60","author":"E Trinka","year":"2019","unstructured":"Trinka E, Kwan P, Lee B, Dash A. Epilepsy in Asia: disease burden, management barriers, and challenges. Epilepsia. 2019;60(S1):7\u201321.","journal-title":"Epilepsia"},{"issue":"3","key":"3432_CR20","doi-asserted-by":"publisher","first-page":"6202","DOI":"10.4238\/2014.August.15.3","volume":"13","author":"DH Huang","year":"2014","unstructured":"Huang DH, Zheng JO, Chen J, Yu L. Treatment gaps of epilepsy and retention rates of sodium valproate in rural Guangxi, China. Genet Mol Res. 2014;13(3):6202\u201312.","journal-title":"Genet Mol Res"},{"issue":"4","key":"3432_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S1474-4422(21)00023-5","volume":"20","author":"D Ding","year":"2021","unstructured":"Ding D, Zhou D, Sander JW, Wang W, Li S, Hong Z. Epilepsy in China: major progress in the past two decades. Lancet Neurol. 2021;20(4):316\u201326.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3432_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.yebeh.2011.10.018","volume":"23","author":"P Yu","year":"2012","unstructured":"Yu P, Zhu G, Ding D, et al. Treatment of epilepsy in adults: expert opinion in China. Epilepsy Behav. 2012;23(1):36\u201340.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"3432_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","volume":"22","author":"DK Angeles","year":"1981","unstructured":"Angeles DK. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22(4):489\u2013501.","journal-title":"Epilepsia"},{"issue":"6","key":"3432_CR24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase\u00a03, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108.","journal-title":"Epilepsia"},{"key":"3432_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","volume":"118","author":"S Mulheron","year":"2024","unstructured":"Mulheron S, Leahy TP, McStravick M, Doran R, Delanty N. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis. Seizure-Eur J Epilepsy. 2024;118:80\u201390.","journal-title":"Seizure-Eur J Epilepsy"},{"issue":"23","key":"3432_CR26","doi-asserted-by":"publisher","first-page":"13014","DOI":"10.3390\/ijms252313014","volume":"25","author":"B B\u0142aszczyk","year":"2024","unstructured":"B\u0142aszczyk B, Czuczwar SJ, Miziak B. Cenobamate, a new promising antiseizure medication: experimental and clinical aspects. IJMS. 2024;25(23):13014.","journal-title":"IJMS"},{"issue":"11","key":"3432_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/epi.16718","volume":"61","author":"M Guignet","year":"2020","unstructured":"Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia. 2020;61(11):2329\u201339.","journal-title":"Epilepsia"},{"key":"3432_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","volume":"110","author":"MA Rogawski","year":"2015","unstructured":"Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189\u2013205.","journal-title":"Epilepsy Res"},{"key":"3432_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173117","volume":"879","author":"R Sharma","year":"2020","unstructured":"Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879:173117.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"3432_CR30","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3390\/biom12121784","volume":"12","author":"MP Goldschen-Ohm","year":"2022","unstructured":"Goldschen-Ohm MP. Benzodiazepine modulation of GABAA receptors: a mechanistic perspective. Biomolecules. 2022;12(12):1784.","journal-title":"Biomolecules"},{"issue":"1","key":"3432_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s43141-021-00224-0","volume":"19","author":"A Ghit","year":"2021","unstructured":"Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021;19(1):123.","journal-title":"J Genet Eng Biotechnol"},{"issue":"8","key":"3432_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.seizure.2013.04.015","volume":"22","author":"LJ Greenfield","year":"2013","unstructured":"Greenfield LJ. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure. 2013;22(8):589\u2013600.","journal-title":"Seizure"},{"issue":"9","key":"3432_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.670108","volume":"6","author":"D Zhang","year":"2021","unstructured":"Zhang D, Li X, Ding J, et al. Value of perampanel as adjunctive treatment for partial-onset seizures in epilepsy: cost-effectiveness and budget impact analysis. Front Public Health. 2021;6(9):670108.","journal-title":"Front Public Health"},{"key":"3432_CR34","doi-asserted-by":"publisher","first-page":"949783","DOI":"10.3389\/fped.2022.949783","volume":"10","author":"Y Li","year":"2022","unstructured":"Li Y, Guo HL, Zhang YY, et al. Plasma lacosamide monitoring in children with epilepsy: focus on reference therapeutic range and influencing factors. Front Pediatr. 2022;10:949783.","journal-title":"Front Pediatr"},{"key":"3432_CR35","doi-asserted-by":"publisher","first-page":"109353","DOI":"10.1016\/j.yebeh.2023.109353","volume":"146","author":"R Zhou","year":"2023","unstructured":"Zhou R, Qu R, Liu M, et al. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: a prospective study evaluating efficacy, tolerability, and behavior. Epilepsy Behavior. 2023;146:109353.","journal-title":"Epilepsy Behavior"},{"key":"3432_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","volume":"96","author":"C Brandt","year":"2022","unstructured":"Brandt C, S\u00e1nchez-\u00c1lvarez JC, Steinhoff BJ, Milanov I, Serratosa JM. Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure. 2022;96:86\u201393.","journal-title":"Seizure"},{"issue":"2","key":"3432_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14737175.2020.1707668","volume":"20","author":"A Verrotti","year":"2020","unstructured":"Verrotti A, Tambucci R, Di Francesco L, et al. The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. Expert Rev Neurother. 2020;20(2):167\u201373.","journal-title":"Expert Rev Neurother"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03432-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03432-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03432-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:29Z","timestamp":1771268609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03432-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3432"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03432-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peimin Yu, Xintong Wu, Li Cui, Songqing Pan, Yanbing Han, Huiqin Xu, Suiqiang Zhu, Xuefeng Wang, Huapin Huang, Tiancheng Wang, Weiping Liao, Ming Zhang, Liou Tang, Hongbin Sun, Bing Qin, Zhiping Hu, Juan Feng, Yangmei Chen, Meiyun Zhang, Qifu Li, Xiong Han, Bo Xiao, Huisheng Chen, Luoqing Li, Yanran Liang, Zhen Hong, and Dong Zhou have no conflicts of interest to declare. All authors have read and approved the manuscript. Yutong Liu and Hui Ye are employees of Ignis Therapeutics (Shanghai) Limited, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This trial on which the post\u00a0hoc analyses are based was conducted in accordance with the International Conference on Harmonisation notes for Guidance on Good Clinical Practice, in addition to any applicable country-specific regulations and the Declaration of Helsinki. The original trial protocols were approved by independent ethics committees or institutional review boards according to local regulations at each site. Informed consent was obtained from all individual participants included in the study before enrolment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}